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permanently integrated in the pig genome (PERV A and
B) expressed in pig hearts, spleens, and kidneys and dif-
fering in their envelope proteins.5 Taken together, these
findings strongly questioned the safety of xenografts.
Nevertheless, at present there is no evidence6 for cross-
species transmission of PERV in patients who have
been treated with a multitude of living pig tissues, such
as extracorporeal liver and kidney and splenic perfu-
sion, bioartificial liver perfusion, pig skin grafts, and
pancreatic islet cell transplants. However, most of these
patients were exposed to porcine tissue only for a short
time and not or only partially immunosuppressed. In
contrast, in patients receiving xenotransplants, initially
a high dose of immunosuppression and subsequent life-
long immunosuppression will be mandatory, thus facil-
itating possible PERV infection.
Until now, pretreated pig heart valves widely used for
aortic valve replacement/mitral valve replacement
(AVR/MVR) have been neglected as a possible source
for transmission of PERV in human subjects. We there-
fore investigated the potential of pig heart valves to
cause PERV infection in patients who underwent
AVR/MVR. For this purpose, we explanted native
T o amend the shortage of donor organs, investigatorshave directed much attention toward the possibility
of xenotransplantation.1 In this context, however, there
is much concern in the recent literature about possible
transmission of a porcine endogenous retrovirus
(PERV)2 because many patients have been exposed to
pig tissue and organs for various therapeutic reasons.
Patience, Takeuchi, and Weiss3 demonstrated the
release of a C-type retrovirus from pig kidney cell lines
(PK 15) capable of infecting human cells in vitro.
Mitogenic stimulation of pig peripheral blood mono-
cytes (PBMCs), as shown by Wilson and associates,4
produces a virus infectious to HEK 239 and HeLa cell
lines. Further studies revealed at least 2 types of PERV
Objective: Replacement of heart valves in human subjects has become a rou-
tine procedure in cardiac operations. We sought to investigate whether com-
mercially available glutaraldehyde-fixed porcine heart valve prostheses
cause porcine endogenous retrovirus infection in human subjects because
recent studies revealed that human cells can be infected with porcine
endogenous retrovirus.
Methods: Blood samples of 18 patients who underwent aortic or mitral valve
replacement with porcine heart valves were collected 6 months to 3 years
after operation and tested for porcine endogenous retrovirus by means of
polymerase chain reaction and reverse transcriptase–polymerase chain reac-
tion. In addition, we tried to trace porcine endogenous retrovirus in 3 com-
mercially available, glutaraldehyde-fixed, porcine heart valves.
Results: Porcine endogenous retrovirus can be easily detected in native
porcine heart valves and degrades completely within 1 week of fixation in
glutaraldehyde. In all 3 commercially available porcine heart valves, no
traces of porcine endogenous retrovirus were found. All blood samples
showed negative test results for the porcine endogenous retrovirus genome.
Conclusion: Our results indicate that glutaraldehyde fixation of porcine heart
valves reliably prevents cross-species transmission of porcine endogenous
retrovirus. (J Thorac Cardiovasc Surg 2001;121:697-701)
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porcine heart valves that were analogous to commer-
cially available valves fixated in 3% glutaraldehyde.
We then assessed after which time period PERV was no
longer detectable by means of polymerase chain reac-
tion (PCR) and reverse transcription PCR (RT-PCR).
Second, 3 commercially available porcine heart valves
(Carpentier-Edwards, Baxter Healthcare Corp) used for
AVR and MVR in human subjects were tested for
PERV. Finally, blood samples from 18 patients (9 men
and 9 women; age range, 71-86 years old; average age,
78.4 years) were collected 6 months to 3 years after
AVR/MVR to investigate the possible expression of
PERV DNA-RNA in lymphocytes and in plasma.
Lymphocytes were isolated by means of density gradi-
ent centrifugation by using Ficoll-Paque reagents
(Pharmacia Biotech, Uppsala, Sweden).
Methods
In vitro isolation of PBMCs from whole blood. Ficoll-
Paque gradient was prepared according to the manufacturer’s
instructions. Anticoagulant-treated blood was layered on the
Ficoll-Paque solution and centrifuged at 400g for 40 minutes
at 20°C. Differential migration during centrifugation results
in the formation of layers containing different blood cell
types. First, the upper layer of plasma was discarded. Then
the lymphocyte layer was transferred to a clean centrifuge
tube. Two washing steps followed, adding 3 volumes of bal-
anced salt solution and centrifugation at 100g for 10 minutes
at 20°C. The supernatant was removed, and the lymphocytes
in pellets were homogenized in denaturing solution.
Isolation of DNA and total RNA of PBMCs and tissue.
The cusps of one heart valve and Ficoll-Paque isolated
PBMCs were homogenized in a denaturing solution contain-
ing 4 mol/L guanidine thiocyanate, 25 mmol/L sodium cit-
rate, 0.5% N-lauroyl-sarcosine (Sarkosyl), and 0.1 mol/L 2-
mercaptoethanol. One milliliter of homogenate was mixed
with 0.1 mL of 2 mol/L sodium acetate (pH 4). After several
inversions, 1 mL of water-saturated phenol was added and
thoroughly mixed, and 0.2 mL of 49:1 chloroform/isoamyl
alcohol was added. The suspension was incubated for 15
minutes at 4°C. After centrifugation at 10,000g for 20 min-
utes at 4°C the aqueous RNA-containing phase was trans-
ferred in a second tube. The interphase and lower organic
phase were used to precipitate DNA.
DNA. Per 1 mL of denaturing solution, 0.3 mL of 100%
ethanol was added, incubated for 5 minutes at room temper-
ature, and centrifuged at 2000g for 5 minutes at 4°C. Protein-
containing supernatant was removed, and the DNA pellet was
washed twice in 0.1 mol/L sodium citrate. The DNA pellet
was resuspended in 75% ethanol and incubated for 20 min-
utes at room temperature. The dried DNA pellet was dis-
solved in 8 mmol/L NaOH and centrifuged at 12,000g for 10
minutes. The supernatant was then transferred to a new tube,
DNA was quantitated by reading the A260, and 0.5 to 1 µg
was added to the PCR mix.
RNA. RNA was precipitated by adding 1 mL of 100% iso-
propanol to the aqueous phase, incubating for 30 minutes at
–20°C, and centrifuging at 10,000g for 10 minutes at 4°C.
The RNA pellet was dissolved in 0.3 mL of denaturing solu-
tion and precipitated by adding 0.3 mL of 100% isopropanol,
incubating for 30 minutes at –20°C, and centrifuging at
10,000g for 10 minutes at 4°C. The pellet was resuspended in
75% ethanol, mixed, and incubated for 15 minutes at room
temperature and afterward centrifuged at 10,000g for 5 min-
utes at 4°C. The supernatant was discarded, and the pellet
was dried. RNA was dissolved in 100 to 200 µL of diethyl
pyrocarbonate–treated water, incubated for 15 minutes at
55°C, and stored at –70°C. RNA was quantitated by reading
the A260 and A280. One microgram was used for RT-PCR.
Isolation of DNA and total RNA from cell cultures.
Cellular DNA and total RNA of 2 to 5 × 106 human cells and
porcine cells out of cell culture were prepared by using TRI
Reagent (Molecular Research Center, Inc, Cincinnati, Ohio)
according to the manufacturer’s instructions.
Potentially contaminating DNA in the total RNA prepara-
tion was digested by means of DNAse treatment (Boehringer
Mannheim, Division of Roche Pharmaceuticals, Mannheim,
Germany). For 10 µg, total RNA was 10 U of RNAse-free
DNAse I, 40 U/µL RNAse inhibitor (Boehringer Mannheim),
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Fig 1. PCR of DNA of glutaraldehyde-fixed porcine heart valves. Lane 1, Marker; lane 2, positive control with
PK 15 cells; lane 3, marker; lanes 4 to 6, human vascular primary cells; lanes 7 to 9, DNA of glutaraldehyde-
fixed porcine heart valves; lane 10, negative control with human endothelial cells; lane 11, marker.
1 mol/L MgCl2, and 0.1 mol/L dithiothreitol used and incu-
bated for 15 minutes at 37°C, followed by a phenol-chloro-
form extraction.
Purification of viral RNA from plasma. For purification
of viral RNA from human plasma, Qiagen QiAamp viral
RNA Mini Kit (Qiagen GmbH, Hilden, Germany) was used.
Viral RNA preparation was done according to the manufac-
turer’s instructions.
PERV-specific PCR and RT-PCR. These methods were
performed according to the PERV pol-specific PCR/RT-PCR of
Patience, Takeuchi, and Weiss3 and porcine-specific RT-PCR of
Heneine and associates.7 For cDNA synthesis, 1 µg of total
RNA and AMV-RT (Boehringer Mannheim) was used. PCR
was done with 1 µg of DNA. PCR products were separated on
2% agarose gel in an ethidium bromide-TAE buffer. The sensi-
tivity of our PCR and RT-PCR averages 50 PERV copies in a
total of 1 million RNA or DAN copies (data not shown).
Glutaraldehyde fixation of porcine heart valves.
Twenty-two percent glutaraldehyde (Merck KGaA,
Darmstadt, Germany) was diluted with phosphate-buffered
saline solution to a final concentration of 3%. Fresh isolated
porcine heart valves with a part of the heart muscle and a part
of the aorta were incubated in the 3% glutaraldehyde solution
by 4°C. DNA and RNA of one cusp and 100 mg of aortic tis-
sue were isolated, as described previously.
Results
PERV sequences in glutaraldehyde-fixed native
porcine heart valves. PERV sequences, DNA (Fig 1)
and RNA (Fig 2), were clearly detectable 1 day after
fixation of native porcine heart valves. After 5 days,
there was only a weak signal for PERV RNA, but DNA
remained detectable. In contrast, the intensity of
porcine-specific signals did not decrease as fast (Fig 2).
PERV sequences in commercially available
valves. Two cusps of one heart valve and half of the
surrounding anulus from 3 different porcine heart
valves were used to isolate RNA and DNA. Only a
negligible amount of RNA could be isolated, indicat-
ing that glutaraldehyde fixation of the tissue is
responsible for the entire degradation of RNA. The
prepared porcine DNA was used in PERV pol-specif-
ic PCR, as shown in Fig 3. Although porcine DNA
was detectable (lane 8), PERV-specific sequences
were impossible to amplify (lane 2-7). In conclusion,
our results indicate that commercial glutaraldehyde-
fixed heart valves do not carry PERV DNA or at least
not a detectable amount of endogenous retroviral
sequences.
PERV sequences in patients after valve replace-
ment. Porcine plasma, which was treated in the same
manner as the 18 patient probes, served as a positive
control. These controls constantly yielded a distinc-
tive PERV-specific signal, whereas all patient samples
remained negative up to 3 years after valve replace-
ment (Fig 4).
Examination of PBMCs of patients after AVR/MVR
by means of PCR revealed negative results in all 18
recipients (Fig 5). Positive controls (porcine PBMCs)
uniformly showed a strong signal for PERV
sequences. Plasma and PBMC probes from 4 young
and healthy volunteers were obtained and served as
negative controls.
Thus, up to 3 years after implantation of glutaralde-
hyde-fixed porcine heart valves, no cross-species trans-
mission of PERV in human subjects occurred.
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Fig 2. RT-PCR of RNA of glutaraldehyde-fixed porcine heart valves. Lane 1, Marker; lanes 2 to 6, RT-PCR with
PERV-specific primers: RNA of glutaraldehyde-fixed native porcine heart valves (days 1, 2, and 5; lanes 2-4), pos-
itive control (PK 15, lane 4), and negative control (human endothelial cells, lane 5); lane 7, marker; lanes 8 to 12,
RT-PCR with porcine-specific primer: RNA of glutaraldehyde-fixed native porcine heart valves (days 1, 2, and 5;
lanes 8-10), positive control (PK 15, lane 11), and negative control (human endothelial cells, lane 12); lane 13,
marker; lane 14, RT-PCR of RNA from PK 15 cells with PERV-specific primer; lane 15, RT-PCR of RNA from
PK 15 cells with porcine-specific primer.
Discussion
There are still major doubts about the safety of pig
xenografts in terms of cross-species infection of human
subjects with PERV2 enhanced by recent studies,
demonstrating that PERV is capable of infecting human
cell lines in vitro.3 However, this does not entirely
reflect the situation in vivo. Patients who had been
exposed, although predominantly only for a short peri-
od of time, to pig tissue in various clinical settings had
negative test results for PERV.6 These data are only
applicable with certain reservations to future transplan-
tation of xenografts. First, the patients in this study
were not immunosuppressed, which is still indispen-
sable for a successful transplantation of organs in gen-
eral. Second, Paradies and associates6 did not provide
any data about patients who were treated for a relative-
ly short period of time.
The use of porcine heart valves has become a routine
procedure in cardiac operations. We now wanted to
investigate whether we would be able to trace PERV in
porcine heart valves commonly implanted in human
subjects and whether patients who underwent
AVR/MVR with biologic prostheses have been infect-
ed with PERV.
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Fig 3. PERV sequences in 3 different commercially available heart valves. Lane 1, Marker; lanes 2 to 7, PCR
of DNA and RT-PCR of RNA from 3 different heart valves; lane 8, positive control (PCR of DNA from native
porcine heart valve with porcine-specific primer); lane 9, negative control (PCR of DNA from native porcine
heart valve with human-specific primer); lane 10, marker.
Fig 4. Plasma probes of patients after heart valve replacement. Lane 1, Marker; lanes 2 to 19, PCR of DNA
from patient plasma probes with PERV-specific primers; lane 20, PCR of porcine plasma with PERV-specific
primers; lane 21, PCR of porcine plasma with porcine-specific primers; lane 22, negative control (human
endothelial cells with PERV-specific primer); lane 23, positive control (PK 15 with PERV-specific primer); lane
24, marker.
Our first step was to examine glutaraldehyde-fixed
native porcine heart valves to assess the degrading time
of PERV RNA-DNA. As we have shown, traces of
PERV RNA-DNA are only detectable within the first
week after glutaraldehyde fixation. These results
already indicated that glutaraldehyde-fixed porcine
heart valves carry a low risk of interspecies PERV
transmission. To verify this assumption, we extracted
DNA and RNA of commercially available heart valves
usually implanted in human subjects. According to our
PCR and RT-PCR results, no fragments of PERV
sequences were detectable, making further transmis-
sion of PERV from porcine heart valves unlikely.
Taken together, these results reveal fragments of
PERV sequences to completely degrade in glutaralde-
hyde-fixed porcine heart valves within 1 week.
Therefore, it is not surprising that we were unable to
trace PERV DNA-RNA in commercially available bio-
logic heart valves, which were originally destined for
clinical use.
Nevertheless, one cannot exclude transmission of
PERV to human subjects if porcine glutaraldehyde-
fixed valves are implanted because porcine cells con-
taining endogenous retrovirus remain present in the
graft. Despite this low probability, we examined blood
samples of patients after AVR/MVR with biologic
heart valves. We failed to detect PERV DNA-RNA iso-
lated from lymphocytes and plasma of patients who
underwent AVR/MVR with porcine heart valves. In
these patients, cardiac operations have been performed
6 months to 3 years before examination, providing
enough time for possible PERV infection to occur.
In conclusion, we were not able to trace PERV trans-
mission or infection in patients who underwent valve
replacement with porcine heart valve prostheses nor
could we detect PERV in porcine heart valves com-
monly used in human subjects. From our results, fixa-
tion of porcine heart valves in glutaraldehyde, as used
commercially, is entirely sufficient to prevent inter-
species transmission of PERV.
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Fig 5. PCR of DNA from PBMCs in patients after heart valve replacement. Lane 1, Marker; lanes 2 to 10, PBMCs
of patients 1 to 9; lane 11, positive control (porcine PBMCs with PERV-specific primers); lane 12, negative con-
trol (human PBMCs with PERV-specific primers); lane 13, marker; lanes 14 to 22, PBMCs of patients 10 to 18;
lane 23, PCR of DNA from porcine PBMCs with porcine-specific primers; lane 24, PCR of DNA from human
PBMCs with porcine-specific primers; lane 25, marker.
